×
Vote

Healthcare, Pharma and Biotech: Divergent investment opportunities in Asia

Sean Wu

Laurence
Tam

Mi Hyun
Kim

Binay Singh

Alexis Yan

Jack Lin

Industry Sectors

Macro Sectors

Countries & Regions

Leader in the Institutional Investor All-Asia 2024 Rankings

In Institutional Investor’s All-Asia 2024 surveys, the Firm was voted:

• #1 2024 All-Asia Research Team
• #1 2024 Asia’s Top Corporate Access Providers
• #1 2024 All-Asia Trading Team
• #2 2024 All-Asia Sales Team

We are proud to continue our legacy of strong performance in Institutional Investor’s rankings across all four survey categories. Morgan Stanley Research delivers thought leadership and actionable investment ideas through our Blue Papers and Insights, which focus on the market’s most impactful trends and debates. Our proprietary research product suite has at its core the insights of a highly experienced team and a rigorous review process.

Source: Institutional Investor’s surveys 2024

Vote For Our Analysts

Morgan Stanley appreciates your support in the Institutional Investor All-Asia Research Team Survey

The content of this site may not be reprinted, sold or redistributed in whole or in part without prior written consent from Morgan Stanley. The research and other information provided on this site speaks only as of its date. We have not undertaken, and will not undertake, any duty to update the research or information contained on this site or otherwise advise you of changes in our opinion or in the research or information. Continued access to the research and other information is provided for your convenience only, and is not a republication or reconfirmation of the opinions or information contained therein.